Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance - Wikidata - thesis-toulmin - TriplyDB

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

http://www.wikidata.org/entity/Q27654007

about

Structural basis of activation-dependent binding of ligand-mimetic antibody AL-57 to integrin LFA-1 How Natalizumab Binds and Antagonizes 4 Integrins Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)Towards automated crystallographic structure refinement with phenix.refine Local Geometry and Evolutionary Conservation of Protein Surfaces Reveal the Multiple Recognition Patches in Protein-Protein Interactions Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients.GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors.Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate Sevoflurane binds and allosterically blocks integrin lymphocyte function-associated antigen-1.Psoriasis and physical activity: a review.On the potential involvement of CD11d in co-stimulating the production of interferon-γ by natural killer cells upon interaction with neutrophils via intercellular adhesion molecule-3.Host ICAMs play a role in cell invasion by Mycobacterium tuberculosis and Plasmodium falciparum.Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection.Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis.NMR characterization of the conformational fluctuations of the human lymphocyte function-associated antigen-1 I-domain Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.

P2860

Q27657681-B1A7E4FE-118D-420A-B5C4-E89B3155C869 Q27679979-C996558E-ED43-475C-BC59-68AB03CBEC7D Q27681464-6C23773C-B3B9-4EDD-A2FB-B6232A2B828E Q27860678-02C7A1C9-2A51-4304-AD95-E8C56681B37B Q28551667-585854A1-1D3C-4908-9520-B9B28A158B2D Q33571293-0A8F2159-A16C-44E5-A981-594F0D655F6C Q33892532-9ED04552-CB26-4946-BD46-E2CAE263DDDA Q34021856-2AEF93E4-6482-4354-9799-71BC943CC5AA Q35637379-4867BA6A-19E5-4ACB-88DA-784B1D0E50A8 Q36296686-2B048849-0068-4FAA-8E08-8CB2FFF4C362 Q37554685-3349845E-1935-4AED-A59A-7180C7415673 Q37990043-09B99586-2B5E-4206-B273-84B77A2A7BC9 Q38621013-16ABD1D8-2A9D-4C57-A6A9-EC3624E0F4D1 Q38920235-4D009F24-1323-4E55-BDF9-E33A4CF39368 Q39337514-8CA0BF19-AC8A-409A-A931-87191E55C2B7 Q39648047-B2FD20BB-C16E-4483-8BC2-F31A51692419 Q41899890-95A095F3-F87F-4261-81D0-0DCCEE940769 Q42550650-CC3E1961-6C0B-490A-8EB8-6BA71FC6267F Q47597795-9B6AF77E-AE53-480D-937B-065D04FF4DA9

P2860

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

http://www.wikidata.org/entity/Q27654007

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@ast

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@en

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@nl

type

label

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@ast

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@en

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@nl

prefLabel

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@ast

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@en

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@nl

P1433

Q27654007-E6350C54-326D-4591-9E9B-2F31BC57D78B

P1476

Q27654007-46520AD9-6508-476C-A258-452A9A2DDEA7

P2093

Q27654007-13E239F2-97D4-486D-B51D-80FAE90E1070

Q27654007-2230A5AE-C614-4CEC-BB58-690AAA6DA2D1

Q27654007-75EE6099-1D64-42AE-BE6D-AFD1871C8D01

Q27654007-959061EA-475C-49FE-9589-C4F1B924127A

Q27654007-A4A64B7F-26E2-48F1-A386-5BD9C6B140D8

Q27654007-BB071289-56FB-4F17-A510-336608EA6907

Q27654007-C6CA0614-03A7-4790-9406-EFBC7199795B

Q27654007-CB152D4D-F26D-43A9-8036-C8D4545F63FD

P2860

Q27654007-0D86FE23-F463-4AA8-A23F-4865627B94CC

Q27654007-101366C2-4A9A-4C7A-99EE-BE494C67E475

Q27654007-167323AE-6438-46D6-A552-5C10649DDA48

Q27654007-1FC56BB3-1728-4809-8003-6EE775B71F37

Q27654007-256A338D-0C7E-44C2-B1DC-0C8226B94D18

Q27654007-26E963FA-E059-44AE-973B-160E85ACE971

Q27654007-2D598988-D886-4AF4-A898-6328EDC7BC1C

Q27654007-318A3670-DAD1-4FBF-AAF5-E512B4996E13

Q27654007-330CC4EA-5931-41B6-92D5-19C2CAF06C90

Q27654007-3826F15A-0C79-464A-BE0F-5CFA274675A9

P304

Q27654007-30445B2E-67F8-4EDC-A601-888D3DC6102A

P31

Q27654007-8BEA6899-9267-4FBB-842B-701355E502A0

P356

Q27654007-ADB7D97D-964B-4E78-9C62-5EA3FFE45A7B

P407

Q27654007-217B8DFE-FDE3-4969-8D80-78FF24130892

P433

Q27654007-C0C90895-A1B9-4C10-A139-2820880FBD52

P478

Q27654007-8CA1D7E6-E0D5-42F4-8712-3037DB5C77CA

P577

Q27654007-C2A53D10-3191-4EF3-9FA9-D91B3E3219A1

P5875

Q27654007-7479EC6C-231B-4869-BD09-1810A9D19386

P698

Q27654007-9611477C-63B6-4A04-9FF2-04D608C4D5D2

P932

Q27654007-06D31C09-4417-4180-9CAB-A8DD1BAA33BB

P356

PNAS.0810844106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance

@en

P2093

Baozhen Peng

http://www.w3.org/2001/XMLSchema#string

Daipong Zhang

http://www.w3.org/2001/XMLSchema#string

Hao Wang

http://www.w3.org/2001/XMLSchema#string

Jianping Ding

http://www.w3.org/2001/XMLSchema#string

Meilan Zhang

http://www.w3.org/2001/XMLSchema#string

Sheng Hou

http://www.w3.org/2001/XMLSchema#string

Sheng Li

http://www.w3.org/2001/XMLSchema#string

Yajun Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin

The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand

Structural definition of a conserved neutralization epitope on HIV-1 gp120

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

Processing of X-ray diffraction data collected in oscillation mode

Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain

NMR solution structure of the inserted domain of human leukocyte function associated antigen-1

Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation.

Crystal structure of the alpha1beta1 integrin I domain in complex with an antibody Fab fragment

Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein

P304

4349-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0810844106

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24174743

http://www.w3.org/2001/XMLSchema#string

P698

19258452

http://www.w3.org/2001/XMLSchema#string

P932

2657446

http://www.w3.org/2001/XMLSchema#string